George Parker
Director/Board Member at FIRST REPUBLIC BANK
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Tom Barrack | M | 77 |
DigitalBridge Operating Co. LLC
 DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 28 years |
| Richard Saltzman | M | 67 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | - |
| Nancy Curtin | F | 66 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 10 years |
| Darren J. Tangen | M | 53 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 19 years |
| John A. Somers | M | 80 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 9 years |
| Michael Roffler | M | 53 | 15 years | |
| Charles W. Schoenherr | M | 64 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 4 years |
| Gregory Bielli | M | 63 | 11 years | |
| Launny Steffens | M | 82 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 9 years |
| Jon Fosheim | M | 73 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 7 years |
| Kevin P. Traenkle | M | 54 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 16 years |
| Douglas Crocker | M | 83 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 4 years |
| Justin Metz | M | 50 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 4 years |
| Robert Velasquez | M | 57 | 10 years | |
| Jeannie Diefenderfer | F | 63 | 4 years | |
| Michael Selfridge | M | 56 | 12 years | |
| Brian Lee | M | - | 3 years | |
| Mollie Richardson | F | 45 | 21 years | |
| Neale W. Redington | M | 57 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | - |
| Olga Tsokova | F | 50 | 9 years | |
| Severin White | M | - | 4 years | |
| Sandra Hernández | M | 66 | 14 years | |
| Dale Reiss | F | 76 | 5 years | |
| Kristen Whealon | F | - | 7 years | |
| Gregory McCray | M | 61 | 3 years | |
| Sháka Rasheed | M | 52 | 3 years | |
| Ronald Sanders | M | 60 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | - |
| Steven Betts | M | 66 | 10 years | |
| Reynold Levy | M | 78 | 11 years | |
| Daniel Tisch | M | 72 | 12 years | |
| David Hamamoto | M | 64 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | 2 years |
| Michael Winer | M | 68 | 23 years | |
| Boris Groysberg | M | 52 | 9 years | |
| Frank Fahrenkopf | M | 85 | 16 years | |
| Anthony Leggio | M | 71 | 12 years | |
| Justin Gibson | M | - | 12 years | |
| Hana Yang | F | - | 9 years | |
| Stephanie Bontemps | F | - | 16 years | |
| Neal Holland | M | 47 | 2 years | |
| William Francis Hughes | M | 49 | 7 years | |
| Paul V. Varisano | M | 43 | 5 years | |
| Giles Proctor | M | - | 4 years | |
| Shilla Kim-Parker | F | 41 | 2 years | |
| Walter Kortschak | M | 64 | 14 years | |
| Sean Kedrowski | M | - | 7 years | |
| William Ward | M | - | 10 years | |
| Albert Osterloh | M | - | 2 years | |
| Michele Celestino | F | - | 23 years | |
| Hugh McMahon | M | 57 | 23 years | |
| Liam Stewart | M | 46 | 4 years | |
| Matty Yohannan | M | - | 4 years | |
| Robert Lee Thornton | M | - | 20 years | |
| James Hughes | M | 66 | 7 years | |
| Jeffrey Ginsberg | M | 60 | 7 years | |
| Mark M. Hedstrom | M | 66 |
DigitalBridge Operating Co. LLC
DigitalBridge Operating Co. LLC Financial ConglomeratesFinance DigitalBridge Operating Co. LLC engages in the provision of real estate investment services. The company is headquartered in Los Angeles, CA. | - |
| Frank Saracino | M | 57 | 9 years | |
| Susie Cranston | F | 46 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gordon M. Bethune | M | 82 | 10 years | |
| Joel A. Fernandes | M | 54 |
Threshold Pharmaceuticals, Inc.
 Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
| Jacky Wu | M | 41 | 4 years | |
| Hafize Erkan | M | 44 | 7 years | |
| Katherine August-deWilde | F | 76 |
Stanford Graduate School of Business
| 41 years |
| Barry Zoeller | M | - | 19 years | |
| Michael S. Ostrach | M | 72 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 1 years |
| Jody Lindell | F | 72 |
Stanford Graduate School of Business
| 13 years |
| Jeff Bird | M | 63 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 16 years |
| Gregory Brenneman | M | 62 | 6 years | |
| Stewart M. Kroll | M | 65 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 11 years |
| Jason Bender | M | 54 | 23 years | |
| Joseph M. Petitti | M | - | - | |
| Lamphung Ngo-Burns | F | 58 | 7 years | |
| Laura G. Hansen | M | - |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 years |
| Robert A. Alter | M | 73 | 5 years | |
| David Parkinson | M | 73 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
| Gregory J. Tobias | M | 59 | 4 years | |
| Kent Giles Snyder | M | 87 | 16 years | |
| Daniel Richey | M | - |
Stanford Graduate School of Business
| 2 years |
| Shannon Houston | F | - | - | |
| Paul W Campbell | M | - |
Stanford Graduate School of Business
| 2 years |
| Kirk Holmes | M | - |
Stanford Graduate School of Business
| 5 years |
| Brian W. Grant | M | - | - | |
| Walter Brown | M | 84 |
Stanford University
| 3 years |
| May Chan | F | 50 | - | |
| Harold Selick | M | 69 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 15 years |
| Alfred T. Spain | M | 79 | 13 years | |
| Pamela Joyner | F | 66 | 19 years | |
| Richard Miles | M | 81 |
Stanford University
| 5 years |
| William Ford | M | 61 |
Stanford Graduate School of Business
| 8 years |
| Bruce Cozadd | M | 60 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 12 years |
| John L. Goolsby | M | 82 | 18 years | |
| Donna L. Hansen | F | - | - | |
| Stewart C. Myers | M | 83 |
Stanford University
| 5 years |
| Dennis F. Mullins | M | 71 | 13 years | |
| Frederick Tuomi | M | 69 | 4 years | |
| Peter D. McDonald | M | 72 | 16 years | |
| David Hoffmann | M | 79 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | - |
| Kevin Efrusy | M | 51 |
Stanford Graduate School of Business
| 9 years |
| George Tidmarsh | M | 64 |
Threshold Pharmaceuticals, Inc.
Threshold Pharmaceuticals, Inc. BiotechnologyHealth Technology Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA | 4 years |
| J. Carter | M | 65 | 2 years | |
| Bechir Pierre | M | - |
Stanford Graduate School of Business
| 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- George Parker
- Personal Network